Watch Video
Immunovaccine Inc. (TSX-V: IMV) is a clinical stage vaccine development company focused on advancing its patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy, infectious diseases and animal health. Click here to learn about the growth strategy that makes Immunovaccine an attractive investment opportunity. Immunovaccine is advancing two DepoVax™-based clinical-stage cancer vaccines which have both been shown to be safe and capable of generating tumor-specific immune responses in Phase I clinical studies. Click here to learn more about these product candidates, as well as the rest of the company’s broad vaccine pipeline.